Connect with us


Bausch + Lomb Patent Was Violated, Court Finds




Vitamin Health agreed to pay a settlement.

BRIDGEWATER, NJ – Bausch + Lomb announced that it has resolved its patent infringement lawsuit with Vitamin Health Inc.

In the settlement, Vitamin Health has agreed to pay an undisclosed sum to Bausch + Lomb, according to a press release from Bausch + Lomb.

The lawsuit, filed in September 2013 in the U.S. District Court for the Western District of New York, accused Vitamin Health of infringing Bausch + Lomb’s patent covering PreserVision AREDS and AREDS 2 Formula eye vitamins. The patent is referred to as “the ‘297 patent.”

The infringement was alleged to have occurred through Vitamin Health’s manufacture and sale of certain Viteyes eye vitamins.


“We are pleased with the findings of the Court, which demonstrates the integrity of our PreserVision AREDS and AREDS 2 Formula eye vitamins to meet the needs of eye care professionals and their patients,” said Joseph Gordon, senior vice president and general manager, Bausch + Lomb Consumer Healthcare. “As the leader in ocular nutrition, Bausch + Lomb is committed to providing the most current, science-based eye vitamin formulations. Therefore, when these or any of our products are infringed, we will vigorously defend our intellectual property and innovations to ensure our customers can continue to rely on products that are based on a robust body of scientific and clinical research.”

On July 25, the court issued a decision and order awarding summary judgment to Bausch + Lomb on its motion that certain of Vitamin Health’s AREDS-based formula and AREDS2-based formula eye vitamins infringed the ‘297 patent. After proceeding to trial, the parties reached a settlement resolving other claims, according to the release.

As part of the settlement, the court issued a consent decree on Dec. 20 reflecting that Vitamin Health has admitted that the ‘297 patent is valid and enforceable and that certain other of Vitamin Health’s AREDS and AREDS 2 Formula eye vitamins infringe the patent, the release stated.

Bausch + Lomb is a Valeant Pharmaceuticals International Inc. company.

Read more from Bausch + Lomb




The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines





Get the most important news and business ideas for eyecare professionals every weekday from INVISION.



Most Popular